What is Roth Capital’s Forecast for MBRX Q1 Earnings?

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at Roth Capital issued their Q1 2025 EPS estimates for Moleculin Biotech in a report released on Thursday, November 14th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings of ($1.26) per share for the quarter. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($8.60) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q2 2025 earnings at ($1.25) EPS, Q3 2025 earnings at ($1.25) EPS and Q4 2025 earnings at ($1.25) EPS.

Several other research analysts also recently issued reports on MBRX. StockNews.com started coverage on shares of Moleculin Biotech in a research report on Wednesday, November 13th. They set a “sell” rating on the stock. Maxim Group decreased their price target on shares of Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 12th.

Moleculin Biotech Price Performance

Moleculin Biotech stock opened at $2.52 on Monday. Moleculin Biotech has a 52 week low of $2.12 and a 52 week high of $15.75. The business’s fifty day moving average is $2.52 and its two-hundred day moving average is $3.28.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC lifted its stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 156,000 shares of the company’s stock after purchasing an additional 7,505 shares during the period. Armistice Capital LLC owned 6.75% of Moleculin Biotech worth $549,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.